Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

Fleischmann, Roy; M. Kremer, Joel; J. Cush, John; Schulze‐Koops, Hendrik; A. Connell, Carol; Bradley, John; Gruben, David; V. Wallenstein, Gene; H. Zwillich, Samuel; S. Kanik, Keith

doi:10.1056/nejmoa1109071

Public

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

Published in New England Journal of Medicine • Aug 8, 2012

Authors:

Roy Fleischmann

Joel M. Kremer

John J. Cush

Abstract

BACKGROUND: Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being investigated as a targeted immunomodulator and disease-modifying therapy for rheumatoid arthritis. METHODS: In this phase 3, double-blind, placebo-controlled, parallel-group, 6-month study, 611 patients were ra...

Subject

Tofacitinib

Medicine

Rheumatoid arthritis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!